Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 4/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16060729 | 0.82 | KMT2A (0.45) | KMT2ACASP3FABP5FABP7MDM2 | |
| SCHEMBL28124877 | 0.82 | KMT2A (0.45) | KMT2ACASP3FABP5FABP7MDM2 | |
| SCHEMBL30983357 | 0.80 | KMT2A (0.43) | KMT2ACASP3FABP5FABP7MDM2 | |
| SCHEMBL28124871 | 0.80 | KMT2A (0.43) | KMT2ACASP3FABP5FABP7MDM2 | |
| SCHEMBL29792137 | 0.79 | KMT2A (0.52) | KMT2ACASP3MDM2PTPN1MDM4 | |
| SCHEMBL29989986 | 0.79 | KMT2A (0.52) | KMT2ACASP3MDM2PTPN1MDM4 | |
| SCHEMBL5323666 | 0.79 | KMT2A (0.52) | KMT2ACASP3MDM2PTPN1MDM4 | |
| SCHEMBL9333701 | 0.79 | KMT2A (0.44) | KMT2ACASP3FABP5FABP7MDM2 | |
| SCHEMBL30074491 | 0.79 | KMT2A (0.52) | KMT2ACASP3MDM2PTPN1MDM4 | |
| SCHEMBL1709129 | 0.79 | KMT2A (0.52) | KMT2ACASP3MDM2PTPN1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246314-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9708363-B2 | Method for cross-linking peptides | UNIVERSITEIT GENT (BE) | 2017-07-18 | — | — | US | disclosed |
| US-20160244481-A1 | METHOD FOR CROSS-LINKING PEPTIDES | UNIVERSITEIT GENT (BE) | 2016-08-25 | — | — | US | disclosed |
| US-9290537-B2 | Method for cross-linking peptides | UNIVERSITEIT GENT (BE) | 2016-03-22 | — | — | US | disclosed |
| US-9192682-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | ENDOCYTE, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20130289239-A1 | METHOD FOR CROSS-LINKING PEPTIDES | UNIVERSITEIT GENT (BE) | 2013-10-31 | — | — | US | disclosed |
| US-8546425-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | ENDOCYTE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | KMT2A 2903/4885CASP3 4393/4885FABP5 217/4885 |
| US-20160244481-A1 | METHOD FOR CROSS-LINKING PEPTIDES | PTMS, VIP, FPR2 | KMT2A 4564/4885CASP3 1433/4885FABP5 1048/4885 |
| US-20130289239-A1 | METHOD FOR CROSS-LINKING PEPTIDES | PTMS, VIP, FPR2 | KMT2A 4564/4885CASP3 1433/4885FABP5 1048/4885 |
| US-20170246314-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | KMT2A 2583/4885CASP3 4211/4885FABP5 336/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KMT2A 3466/4885CASP3 3715/4885FABP5 396/4885 |
| US-20110172254-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | FOLR1, FOLR2, DHFR | KMT2A 2903/4885CASP3 4393/4885FABP5 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.